secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001683168-25-005392
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio reports complete response in cSCC and manufacturing agreement for PH-762
-----------------------------------------------------------------------------

- Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.
- Phase 1b fourth-cohort: one complete pathologic response (100% tumor clearance) in cSCC patient.
- One partial response (>50% clearance) in stage 4 metastatic Merkel cell; two non-responses in cSCC.
- No dose-limiting toxicities; PH-762 well tolerated across all cohorts; no clinical progression.
- Enrolling 5th and expected final cohort in Phase 1b dose escalation study for cutaneous carcinomas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825005392/0001683168-25-005392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825005392/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-005392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer